[{"orgOrder":0,"company":"Rivaara Labs","sponsor":"GC Cell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Autologous T-cell Immunotherapy","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Rivaara Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Rivaara Labs \/ GC Cell","highestDevelopmentStatusID":"12","companyTruncated":"Rivaara Labs \/ GC Cell"}]

Find Clinical Drug Pipeline Developments & Deals by Rivaara Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Rivaara Immune has obtained the exclusive right to develop and commercialize Immuncell-LC® within India for liver cancer.

                          Brand Name : Immuncell-LC

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 03, 2022

                          Lead Product(s) : Autologous T-cell Immunotherapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : GC Cell

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank